Please login to the form below

Not currently logged in
Email:
Password:

Ironwood appoints Edward Owens to board

He brings experience as portfolio manager of Vanguard Health Care Fund

Ironwood Edward OwensIronwood Pharmaceuticals has appointed Edwards Owens to the company's board of directors.

Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for irritable bowel syndrome and constipation.

“After decades of observing companies from the outside, I am excited to be part of what I hope and expect will be one of the next great growth companies in biotech,” said Owens.

“The execution of a successful launch of Linzess should provide our team with the resources to build an exceptional business, focused on improving human health and advancing patient care.”

Owens served at Wellington from 1974 to his retirement in 2012, spending 18 years as portfolio manager for the Vanguard Health Care Fund.

During his tenure, the Vanguard Health Care Fund was the best performing mutual fund among all mutual funds.

Peter Hecht, CEO of Ironwood, commented on the appointment of Owens: “He has deeply probed the strategy, growth, successes and challenges of nearly every company in the healthcare space during his investing career, and we are thrilled to have the opportunity to tap into his insights, business savvy and ownership focus.”

11th March 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics